Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma
髓源性抑制细胞在胶质母细胞瘤局部和全身免疫抑制中的作用
基本信息
- 批准号:10746880
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-07 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccountingAddressAdoptive TransferAttenuatedBehaviorBiologicalBlood VesselsBone MarrowCAR T cell therapyCancer VaccinesCell LineageCell ProliferationCellsChimera organismCirculationClinical TrialsComplementDevelopmentDiseaseDisease OutcomeFemaleFoundationsFrequenciesGene Expression ProfileGenerationsGerm CellsGlioblastomaGrowthImmune EvasionImmune checkpoint inhibitorImmune responseImmunityImmunosuppressionImmunotherapeutic agentImmunotherapyImpairmentIn VitroIncidenceIndividualInfiltrationInterleukin-1 betaInterventionKnock-outLaboratoriesLeftMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of brainMediatingMediatorMusMyeloid-derived suppressor cellsOX40Oncolytic virusesPathogenesisPathway AnalysisPathway interactionsPatient-Focused OutcomesPatientsPeripheralPharmaceutical PreparationsPhasePlayPopulation HeterogeneityPre-Clinical ModelPredispositionPrimary Brain NeoplasmsProductionPrognosisRegulationReportingResearchRoleSerumSex DifferencesT-Cell ActivationT-Lymphocyte and Natural Killer CellTestingTherapeuticTumor ImmunityTumor-associated macrophagesVariantantagonistanti-CTLA4anti-PD-1anti-tumor immune responseautocrinecancer stem cellchemotherapyclinical efficacyclinically relevantcomplement systemdensitydrug candidatedrug repurposingefficacy evaluationexperimental studyfludarabinegenetic signaturegranulocyteimmune activationimmune checkpointimprovedin vitro activityin vivoinhibitorinsightmalemonocyteneoplastic cellnovelpharmacologicpolarized cellprogramsreceptorresponsesexstandard of carestem cell self renewalsuccesstherapeutic targettherapy outcometherapy resistanttranscriptometreatment responsetumortumor growthtumor microenvironmenttumor progressiontumor-immune system interactionstumorigenesis
项目摘要
PROJECT SUMMARY: Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median
survival of up to 20 months. Males have a 1.6-fold higher incidence of GBM compared to females and worse
disease outcome. Standard-of-care treatment and immunotherapies, which are currently in clinical trials, have
had limited success improving patient outcome. An immunosuppressive microenvironment facilitating tumor
progression and restricting anti-tumor immune response likely underlies therapeutic resistance. Although
myeloid-derived suppressor cell (MDSCs) accumulate in patients with malignancies and play a critical role in the
establishment of this immunosuppressive milieu, the mechanisms by which individual MDSC subsets promote
tumorigenesis remain poorly defined. In pre-clinical models, I demonstrated that monocytic MDSCs (mMDSCs)
infiltrated tumor at higher rates in males, while granulocytic MDSCs (gMDSCs) were more abundant in the
peripheral circulation of females. Furthermore, there were more immunosuppressive myeloid cells in the tumors
of male patients and gMDSC gene signature associated with poor prognosis of female patients. MDSC subset
variation also determined sex-specific therapeutic response in preclinical models, including to fludarabine and
anti-IL-1β. I also established that complement component 1q (C1q) is highly expressed by gMDSCs and elevated
in females. Based on these observations, I hypothesize that MDSC subsets promote GBM progression via
distinct mechanisms in a sex-specific manner and that their targeting will improve the efficacy of T cell-activating
strategies. Specific Aim 1 will test the hypothesis that mMDSCs and gMDSCs have distinct roles in local and
systemic immunosuppression in a sex-specific manner. This aim will investigate the changes in tumor growth,
vascular density and immune activation status by adoptively transferring MDSC subsets and selectively depleting
MDSCs in bone marrow chimeras. Specific Aim 2 will test the hypothesis that the unique gene expression
signatures of MDSC subsets makes them susceptible to distinct drugs that can be combined with checkpoint
modulators. Sub-Aim 2A will examine the efficacy of drug candidates on MDSC activity in vitro and in vivo, while
Sub-Aim 2B will attempt to achieve durable anti-tumor immune response by combining MDSC targeting
strategies with anti-PD-1, anti-CTLA-4 and anti-OX40. Specific Aim 3 will test the hypothesis that gMDSC-
derived C1q promotes MDSC lineage commitment and systemic immunosuppression by evaluating tumor
progression and checkpoint response in the absence of C1q. Sub-Aim 3A will use C1qa knockout bone marrow
and C1q receptor inhibitors to determine MDSC fate. Sub Aim 3B will use pharmacological inhibitors combined
with checkpoint modulators. These studies lay the foundation for my future research program and the
development of novel immunotherapies for GBM by addressing variations in anti-tumor immunity, repurposing
drugs and defining targetable pathways. These results are broadly applicable to other cancers and can lead to
advanced treatment opportunities and improved patient outcome.
项目摘要:胶质母细胞瘤(GBM)是最常见的原发恶性脑肿瘤,中位数为
存活时间长达20个月。男性的GBM发病率是女性的1.6倍,情况更糟
疾病结局。目前正在进行临床试验的标准护理治疗和免疫疗法
改善患者预后的成功有限。促进肿瘤生长的免疫抑制微环境
进展和限制抗肿瘤免疫反应可能是治疗抵抗的基础。虽然
髓系来源的抑制细胞(MDSCs)在恶性肿瘤患者体内积聚,在肿瘤的发生、发展中起关键作用。
这种免疫抑制环境的建立以及单个MDSC亚群促进免疫的机制
肿瘤的发生仍然没有明确的定义。在临床前模型中,我证明了单核细胞MDSCs(MMDSCs)
男性浸润性肿瘤的发生率较高,而粒细胞多向干细胞(GMDSCs)在
女性的外周循环。此外,肿瘤中有更多的免疫抑制髓系细胞。
男性患者和gMDSC基因特征与女性患者预后不良相关。MDSC子集
变异也决定了临床前模型中性别特异性的治疗反应,包括对氟达拉滨和
抗IL-1β。我还证实了补体成分1q(C1q)在gMDSCs中高度表达并升高
在雌性身上。基于这些观察,我假设MDSC子集通过以下方式促进GBM进展
性别特异性的不同机制以及它们的靶向性将提高T细胞激活的效率
战略。特定目标1将检验以下假设:mMDSCs和gMDSCs在局部和
全身性免疫抑制以一种性别特有的方式。这一目标将研究肿瘤生长的变化,
过继转移MDSC亚群和选择性去除MDSC对血管密度和免疫激活状态的影响
骨髓嵌合体中的MDSCs。《特定目标2》将检验这样一种假设:独特的基因表达
MDSC亚集的特征使其对可与Checkpoint结合的不同药物敏感
调制器。次级目标2A将检查候选药物在体外和体内对MDSC活性的效果,而
子目标2B将尝试通过结合MDSC靶向来实现持久的抗肿瘤免疫反应
使用抗PD-1、抗CTLA-4和抗OX40的策略。具体目标3将检验gMDSC-
通过评估肿瘤,衍生的C1q促进MDSC的谱系承诺和全身免疫抑制
在没有C1q的情况下进度和检查点响应。SubAim 3A将使用C1qa基因敲除骨髓
和C1q受体抑制剂来决定MDSC的命运。SubAim 3B将联合使用药物抑制剂
带有检查点调制器。这些研究为我未来的研究计划和
通过解决抗肿瘤免疫的变化,重新定位来开发治疗基底膜的新型免疫疗法
药物和确定靶向途径。这些结果广泛适用于其他癌症,并可能导致
先进的治疗机会和改善的患者结局。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Defne Bayik Watson其他文献
Defne Bayik Watson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Defne Bayik Watson', 18)}}的其他基金
Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma
髓源性抑制细胞在胶质母细胞瘤局部和全身免疫抑制中的作用
- 批准号:
10837997 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma
髓源性抑制细胞在胶质母细胞瘤局部和全身免疫抑制中的作用
- 批准号:
10323691 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant